An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
Source: View publication →
The GUSTO-I trial demonstrated that an accelerated infusion of tissue plasminogen activator (t-PA) combined with intravenous heparin significantly reduced 30-day mortality in acute myocardial infarction compared to standard streptokinase regimens.
Key Findings
Study Design
Study Limitations
Clinical Significance
GUSTO-I established accelerated t-PA with intravenous heparin as the superior pharmacological reperfusion strategy for acute myocardial infarction compared to standard streptokinase. Despite a slight increase in hemorrhagic stroke risk, the significant survival advantage cemented accelerated t-PA as the standard thrombolytic regimen worldwide until the advent and widespread implementation of primary PCI.
Historical Context
Prior to GUSTO-I, mega-trials such as GISSI-1 and ISIS-2 had established the life-saving benefits of streptokinase in acute myocardial infarction. However, the comparative efficacy of more fibrin-specific agents like t-PA remained intensely debated. GUSTO-I was designed to definitively test the 'open-artery' hypothesis—that early, rapid, and sustained restoration of normal coronary blood flow translates directly to improved survival. The trial successfully validated this hypothesis and profoundly shaped cardiovascular medicine in the 1990s.
Guided Discussion
High-yield insights from every perspective
How do the mechanisms of action differ between tissue plasminogen activator (t-PA) and streptokinase, and how does this difference explain the requirement for concurrent intravenous heparin with t-PA but not necessarily with streptokinase?
Key Response
t-PA is fibrin-specific and rapidly degrades the clot while leaving most circulating fibrinogen intact, which can lead to a highly prothrombotic state post-lysis that requires IV heparin to prevent reocclusion. In contrast, streptokinase is non-fibrin-specific and causes systemic fibrinogen depletion (a systemic lytic state), which inherently acts as a continuous anticoagulant, making concurrent IV heparin less strictly necessary for maintaining vessel patency.
In the GUSTO-I trial, accelerated t-PA showed a mortality benefit over streptokinase but was associated with a specific severe adverse event. What is this adverse event, and how does its incidence influence patient selection and absolute contraindications for thrombolytic therapy today?
Key Response
t-PA carries a slightly higher risk of hemorrhagic stroke (intracranial hemorrhage) compared to streptokinase (0.72% vs 0.49% in GUSTO-I). Residents must recognize this critical trade-off: a net mortality benefit but an increased ICH risk. This directly informs the absolute contraindications checklist for fibrinolysis in STEMI (e.g., prior hemorrhagic stroke, recent major surgery, active internal bleeding) when evaluating a patient in a non-PCI capable center.
The GUSTO-I angiographic substudy introduced the concept of TIMI flow grades to explain the clinical differences between the treatment arms. How did the differences in TIMI 3 flow rates at 90 minutes between the accelerated t-PA and streptokinase groups validate the 'open-artery hypothesis' in acute myocardial infarction?
Key Response
The GUSTO angiographic substudy demonstrated that accelerated t-PA achieved TIMI 3 (normal) flow in about 54% of patients at 90 minutes, compared to approximately 30% for streptokinase. This early, complete reperfusion directly correlated with improved survival and preserved left ventricular function, definitively establishing that early and complete patency (TIMI 3, rather than just partial TIMI 2 flow) is the primary determinant of the mortality benefit in STEMI.
Given that primary percutaneous coronary intervention (PCI) is now the standard of care for STEMI, how do the core principles established by the GUSTO-I trial regarding 'time to reperfusion' and 'accelerated dosing regimens' continue to inform our modern pharmacoinvasive strategies?
Key Response
GUSTO-I established that 'time is muscle' and that rapid, complete reperfusion saves lives, proving the superiority of a fast-acting, fibrin-specific agent. This paved the way for modern pharmacoinvasive strategies (using tenecteplase, a modified t-PA) for patients presenting to non-PCI centers who cannot be transferred within 120 minutes. The trial teaches us that if PCI is delayed, rapid administration of a fibrin-specific lytic followed by transfer for rescue or routine PCI remains a highly effective, evidence-based paradigm.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The GUSTO-I trial enrolled over 41,000 patients to detect a 1% absolute risk reduction in 30-day mortality. How does this massive sample size requirement reflect the statistical challenges of 'mega-trials' comparing active treatments, and what are the implications for designing modern cardiovascular outcome trials?
Key Response
Detecting small absolute differences between two effective therapies (active-control trials) requires massive statistical power. As baseline standard-of-care improves, expected event rates drop, and the delta between therapies shrinks. Researchers must understand how this mathematical reality drives modern trials toward composite endpoints (e.g., MACE) rather than isolated all-cause mortality, as powering a contemporary trial for a hard mortality endpoint alone has become logistically and financially prohibitive.
GUSTO-I was an open-label trial, largely due to the differing administration protocols of the four regimens. As an editor evaluating this paper, how would you assess the risk of bias introduced by the open-label design, particularly regarding the use of adjunctive therapies and the assessment of the primary mortality endpoint?
Key Response
While all-cause mortality is a hard, objective endpoint relatively resistant to ascertainment bias, an open-label design introduces a significant risk of performance bias. Physicians knowing the patient received a 'superior' or 'newer' drug (t-PA) might treat them more aggressively with other adjunctive measures (e.g., rescue PCI, intra-aortic balloon pumps, blood transfusions). A rigorous reviewer would scrutinize the supplementary data to ensure balanced utilization of downstream non-protocolized interventions across all arms to validate that the mortality benefit was solely due to the lytic strategy.
Although GUSTO-I established accelerated t-PA as superior to streptokinase, current ACC/AHA STEMI guidelines preferentially recommend fibrin-specific agents with single-bolus administration (like tenecteplase) when primary PCI is unavailable. How did the findings and practical limitations of the GUSTO-I t-PA regimen drive the evolution of these current Class I recommendations?
Key Response
GUSTO-I proved the superiority of fibrin-specific agents (t-PA) over non-specific ones. However, the complex weight-based accelerated infusion of t-PA was prone to dosing errors and delays in preparation. This directly drove the biochemical development of single-bolus mutant t-PAs (tenecteplase/TNK), which match or slightly exceed t-PA's efficacy but eliminate infusion complexity. Consequently, current guidelines give single-bolus fibrin-specific agents a Class I recommendation (Level of Evidence A) over standard t-PA infusions to minimize door-to-needle times and reduce medication errors in high-stress emergency settings.
Clinical Landscape
Noteworthy Related Trials
GISSI-1 Trial
Tested
Intravenous streptokinase
Population
Patients with acute MI within 12 hours of symptom onset
Comparator
Standard medical care
Endpoint
21-day overall mortality
ISIS-2 Trial
Tested
Streptokinase, aspirin, or both
Population
Patients with suspected acute MI within 24 hours of symptom onset
Comparator
Placebo infusions and tablets
Endpoint
5-week vascular mortality
ASSENT-2 Trial
Tested
Single-bolus tenecteplase (TNK-tPA)
Population
Patients with acute STEMI within 6 hours of symptom onset
Comparator
Accelerated infusion of alteplase (tPA)
Endpoint
30-day mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis